The Double Edged Sword of Pfizer's Pandemic Profits Pfizer has reported a modest quarterly beat, thanks in part to its successful blood thinner Eliquis, which saw sales soar 19% higher than expectations.
However, the sales of its COVID vaccine Comirnaty plummeted by an astonishing 34%, with Paxlovid's performance not far behind.
This juxtaposition raises more questions than answers about Pfizer's post pandemic strategy and its commitment to addressing pressing health concerns.